global thalassemia market: industry analysis & outlook (2017-2021)
TRANSCRIPT
Global Thalassemia Market:
Industry Analysis & Outlook
-----------------------------------------
(2017-2021)
Industry Research by Koncept Analytics
1
December 2017
Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)
Executive Summary
2Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)
Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is agenetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by twoproteins called alpha globin and beta globin. A person inherits four genes to produce alpha globin protein andtwo genes to produce alpha globin protein from parents. Thalassemia is caused by any abnormality or mutationin one or more genes responsible for hemoglobin production. When a person inherits only one affected genefrom parents then the person becomes a carrier of thalassemia. Since, thalassemia is an inherited disorder; oneof the parents must be a carrier for thalassemia. When both the parents are carriers then the risk of givingbirth to a thalassemia affected child is quite high. Thalassemia is generally of two types: alpha thalassemia andbeta thalassemia.
Globally, thalassemia affects approximately 7% of the population and many of them are transfusion dependentpatients. The global thalassemia market is likely to be driven with the growing market of bone marrowtransplant and blood transfusion therapy, supported by high numbers of transfusion dependent patients.
The U.S. is expected to be the first region to start selling of thalassemia drugs due to developing drug pipelineand later on, market penetration of thalassemia drugs would occur in Europe. U.S. and Europe have highprevalence of severe forms of beta-thalassemia which would result into a high demand for thalassemia drugs infuture.
The global thalassemia market is expected to grow in future with mounting prevalence of thalassemia, risingAsian population, increasing healthcare expenditure, rising spending on pharmaceuticals R&D and stem celltherapy research. Key trends of this market include progressing drug pipeline, rising scope for gene therapyand growing awareness towards thalassemia. However, there are some factors which can hinder growth of themarket including regulatory changes, associated risks and high cost of treatment.
The report “Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analyticsprovides an extensive research and detailed analysis of the present market along with future outlook. Thereport discusses the major growth drivers and challenges of the market, covering U.S, and Europe along withthe global market. The report profiles key players of the market including GlaxoSmithKline Plc, Celgene,Bluebird Bio and Bellicum Pharmaceuticals.
Global thalassemia market is likely to witness growth due to rising global population of thalassemia, increasing development of drug therapies and gene therapies…
3Global Thalassemia Market: Industry Analysis & Outlook
(2017-2021)
• In 2016, population of non-severe patients held ashare of ..% in the global thalassemia populationwhereas severe population held a share of ..%.
• In 2021, global bone marrow market is predicted to bevalued at US$.. billion increasing from US$.. billion in2016, growing at a CAGR of % for the period spanning2016-2021.
• In year 2025, global Luspatercept revenue for beta-thalassemia is expected to reach US$.. million,increasing from US$.. million in 2019, at a CAGR of..%.
Global Bone Marrow Market Forecast by Value (2016-2021)
Global Thalassemia Population by Category (2016)
Global Luspatercept Revenue Forecast for Beta-Thalassemia (2019-2025)
Thalassemia market of the U.S. and Europe are expected to rise in future due to rising population of beta-thalassemia supported by growing number of immigrants from Asian and African countries…
4Global Thalassemia Market: Industry Analysis & Outlook
(2017-2021)
• The U.S. beta-thalassemia patient volume is expectedto reach … in the year 2021, increasing from … in theyear 2016 at a CAGR of ..%.
• In the year 2021, European beta-thalassemiapopulation is expected to reach ..thousand, increasingfrom …thousand in 2016, growing at a CAGR of %.
• In year 2025, European Luspatercept drug revenue ispredicted to be valued at US$.. million, increasing fromUS$.. million in 2020, at a CAGR of ..%.
Europe Beta-Thalassemia Patient Volume Forecast (2016-2021)
The U.S. Beta-Thalassemia Patient Volume Forecast (2016-2021)
Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia (2020-2025)
Koncept Analytics
CS-36, First Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T: +91-120-4130959
M: +91-9871694789
Contact Us:
www.konceptanalytics.com
This is a licensed product of Koncept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create
other works from this report or use them in any way for commercial purpose without our prior permission. Further, you
cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased
the corporate license of this report.
We believe the sources are reliable, but Koncept Analytics does not warranty the accuracy or completeness of the data. The
data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible
efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given
in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.
For Report Purchase Click Below:http://www.konceptanalytics.com/Researchreport/global-thalassemia-market-industry-analysis-outlook-2017-2021-31472.aspx
Disclaimer